Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Huaier Granule in neoadjuvant treatment of triple-negative breast cancer
ChiCTR2400094488Phase 4Not yet recruiting
- Sponsor
- Tongji Hospital
- Start
- Dec 2024
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of huaier granule in triple-negative breast cancer (TNBC) (2 arms), sponsored by Tongji Hospital. Primary endpoint: Rate of pathological complete response (pCR). Planned start Dec 2024; status: not yet recruiting.
02
Drugs
huaier granule
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on ChiCTR2400094488.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094488.